

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad,
Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

February 09, 2024

To,
BSE Limited
Listing Department
Phiroz Jeejeebhoy Tower,
25th Floor, Dalal Street,
Mumbai-400001

Scrip Code – 531960

Sub.: SUBMISSION OF UNAUDITED FINANCIAL RESULTS OF THE COMPANY AND LIMITED REVIEW REPORT THEREON FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

Dear Sir/Madam,

With reference to above subject and pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith a copy of Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2023, prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND-AS) along with the Limited Review Report thereon, as received from the Statutory Auditors. The same was reviewed by the Audit Committee and subsequently, approved by the Board of Directors of the Company at their respective meetings held on Friday, February 09, 2024.

Further, pursuant to Regulation 46 & 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said result will be uploaded on the website of the Company and will be duly published in the required newspapers within prescribed timeframe.

Please acknowledge the same.

Thanking you,

Yours sincerely,

For, KASHYAP TELE-MEDICINES LIMITED

AMIT AGRAWAL
MANAGING DIRECTOR &
COMPLIANCE OFFICER
DIN: 00169061

Encl.: As above

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

**TO THE BOARD OF DIRECTORS OF
KASHYAP TELE-MEDICINES LIMITED**

1. We have reviewed the accompanying Statement of **Un-audited Financial Results** of **KASHYAP TELE-MEDICINES LIMITED** (the "Company") for the quarter and nine months ended **December 31, 2023** (the "Statement") attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The figures for the quarter and nine months ended December 31, 2022 as reported in this Statement were reviewed by predecessor auditor who expressed an unmodified conclusion on those financial results dated February 10, 2023. Figures for the year ended March 31, 2023 as reported in this Statement were audited by predecessor auditor who expressed an



unmodified opinion on those annual financial results dated May 29, 2023. Our report on the Statement is not modified in respect of the above matter.



For, **Ravi Karia & Associates**
Firm Registration No. 157029W
Chartered Accountants

A handwritten signature in blue ink, appearing to read "Ravi Karia".

Ravi Karia
Partner
Membership No. 161201
UDIN: 24161201BKHBZ6263

Place: Ahmedabad
Date: February 09, 2024

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai – 400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2023

(Rs in Lacs Except EPS)

S.No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31-12-23	30-09-23	31-12-22	31-12-23	31-12-22	31-03-23
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	4.55	6.10	5.40	15.30	15.80	19.65
II	Other Income	-	-	0.02	-	0.02	0.02
III	Total Revenue (I + II)	4.55	6.10	5.42	15.30	15.82	19.67
IV	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expense	2.66	2.86	2.46	8.22	7.47	10.20
	(e) Finance Cost	-	-	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-	-	-
	(g) Other expenses	1.78	3.21	2.88	6.77	7.32	9.05
	Total expenses	4.44	6.07	5.34	14.99	14.79	19.25
V	Profit before exceptional and extraordinary items and tax (III-IV)	0.11	0.03	0.08	0.31	1.03	0.42
VI	Exceptional items	-	-	-	-	-	-
VII	Profit Before Tax (V- VI)	0.11	0.03	0.08	0.31	1.03	0.42
VIII	Tax Expense :-						
	(a) Current Tax	0.03	0.01	0.02	0.08	0.26	0.11
	(b) Tax relating to pervious period	-	-	-	-	-	-
	Total Tax Expense	0.03	0.01	0.02	0.08	0.26	0.11
IX	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	0.08	0.02	0.06	0.23	0.77	0.31
X	Profit / (Loss) after Taxes	0.08	0.02	0.06	0.23	0.77	0.31
XI	Other Comprehensive Income	-	-	-	-	-	-
XII	Total comprehensive income for the period (IX+XI)	0.08	0.02	0.06	0.23	0.77	0.31
XIII	Paid-up Equity Share Capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22	477.22	477.22
XIV	Other Equity excluding revaluation reserves						(410.24)
XV	Earnings per equity Share: (not annualised)	0.000	0.000	0.000	0.000	0.002	0.001
	(a) Basic and Dilulted EPS (XII/XIII)						

Place : Ahmedabad

Date : 9th February, 2024

For and on behalf of Board of Directors of
Kashyap Tele - Medicines Limited



Raghav Agrawal
Director/Chief Financial Officer
DIN: 02264149

Notes to Unaudited Financial Results for the Quarter and Nine month ended 31st December, 2023:

- 1 The Unaudited Financial Results of the Company for the quarter and nine month ended on 31st December, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 09th February, 2024.
- 2 The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 'Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and loses the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended).
- 3 The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results for the quarter and nine months ended on 31st December, 2023 in terms of Regulation 33 of the SEBI (Listing obligations and Disclosures Requirements) Regulations, 2015.
- 4 Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
- 5 The Company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'Operating Segments'.
- 6 Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.



Place : Ahmedabad
Date : 9th February, 2024

For and on behalf of Board of Directors of
Kashyap Tele - Medicines Limited




Baghav Agrawal
Director/Chief Financial Officer
DIN: 02264149